Sandbox gc: Difference between revisions
Jump to navigation
Jump to search
(Replaced content with "==2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure==") |
No edit summary |
||
| Line 1: | Line 1: | ||
==2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure== | ==2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure== | ||
==Class I== | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
| colspan="1" style="text-align:center; background: LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"| | |||
'''1.''' | |||
. | |||
([[ACC AHA guidelines classification scheme#Level of Evidence|Class I, Level of Evidence: A]]) | |||
|- | |||
|} | |||
==Class III (No Benefit)== | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
| colspan="1" style="text-align:center; background: LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III (No Benefit)]] | |||
|- | |||
| bgcolor="LightCoral"| | |||
'''1.''' | |||
. | |||
([[ACC AHA guidelines classification scheme#Level of Evidence|Class III, Level of Evidence: A]]) | |||
|- | |||
|} | |||
==Class III (Harm)== | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
| colspan="1" style="text-align:center; background: LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III (Harm)]] | |||
|- | |||
| bgcolor="LightCoral"| | |||
'''1.''' | |||
. | |||
([[ACC AHA guidelines classification scheme#Level of Evidence|Class III, Level of Evidence: A]]) | |||
|- | |||
|} | |||
==Class IIa== | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
| colspan="1" style="text-align:center; background: LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | |||
|- | |||
| bgcolor="LemonChiffon"| | |||
'''1.''' | |||
. | |||
([[ACC AHA guidelines classification scheme#Level of Evidence|Class IIa, Level of Evidence: A]]) | |||
|- | |||
|} | |||
==Class IIb== | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
| colspan="1" style="text-align:center; background: LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]] | |||
|- | |||
| bgcolor="LemonChiffon"| | |||
'''1.''' | |||
. | |||
([[ACC AHA guidelines classification scheme#Level of Evidence|Class IIb, Level of Evidence: A]]) | |||
|- | |||
|} | |||
Revision as of 15:13, 19 October 2017
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Class I
| Class I |
Class III (No Benefit)
| Class III (No Benefit) |
Class III (Harm)
| Class III (Harm) |
Class IIa
| Class IIa |
Class IIb
| Class IIb |